Ionis Pharmaceuticals, Inc. (IONS)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 2:16 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow IONS in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on IONS and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
IONS at a glance
Key statistics
$7.54B
Market capitalization
- Previous close
- $45.40
- Open
- $45.87
- Day range
- $44.74 – $45.87
- Volume
- 982.6K
- Average volume (30 sessions)
- 3.76M
- Shares outstanding
- 166.18M
- Earnings per share
- $(3.40)
- Price / book
- 17.2
- Price / sales
- 8.6
- Beta (1 year, vs SPY)
- 0.51
Where the price sits in its year
52-week range
7% of the range
- Below the 52-week high
- -48.0%
- Above the 52-week low
- +7.1%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $44.09+3.0%
- 50-day average
- $51.25-11.4%
- 200-day average
- $68.25-33.5%
Between the conventional 30 and 70 bands.
+7.1%
1 week
+1.1%
1 month
-15.9%
3 months
-42.6%
Year to date
-37.9%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with IONS
IONS on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on IONS.
See the plans →
Every planScreen names like IONS
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on IONS
Put IONS on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on IONS
See whether there is an open premium alert on IONS, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
IONS headlines
- Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
GlobeNewswire Inc. · Sep 15, 2026
- Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS
GlobeNewswire Inc. · Jul 28, 2026
- Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market
Benzinga · Mar 26, 2026
- GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies
Benzinga · Jan 7, 2026
- Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial
Benzinga · Sep 22, 2025
- Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
Benzinga · Aug 21, 2025
SEC Form 4, most recent first
Insider filings
Swayze Eric
−125
EVP Research · Option exercise
· Oct 15, 2026
Swayze Eric
+125
EVP Research · Option exercise
· Oct 15, 2026
Swayze Eric
−53
EVP Research · Open-market sale
$2.31K · Oct 16, 2026
Devers Shannon L.
+2.8K
EVP, Chief Human Resources Ofc · Option exercise
· Oct 15, 2026
Devers Shannon L.
−1.4K
EVP, Chief Human Resources Ofc · Open-market sale
$59.08K · Oct 16, 2026
Devers Shannon L.
−2.8K
EVP, Chief Human Resources Ofc · Option exercise
· Oct 15, 2026
Birchler Brian
+58
EVP, Corp and Development Ops · Other acquisition or disposition
$2.98K · Aug 31, 2026
O'NEIL PATRICK R.
+63
EVP CLO & General Counsel · Other acquisition or disposition
$3.23K · Aug 31, 2026
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- Carlsbad, CA
- Employees
- 1,402
- Listed since
- May 17, 1991
- Website
- ionis.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.